Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LSS | P48449 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 10/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227653 | 1.00 | CYP1A2 (0.47) | CYP1A2LSSCNR2EPHX1S1PR2 | |
| SCHEMBL13095873 | 1.00 | CYP1A2 (0.47) | CYP1A2LSSCNR2EPHX1S1PR2 | |
| SCHEMBL14104023 | 0.98 | CYP1A2 (0.48) | CYP1A2LSSCNR2EPHX1 | |
| SCHEMBL4843185 | 0.92 | CYP1A2 (0.56) | CYP1A2LSSCNR2 | |
| SCHEMBL6719013 | 0.88 | EPHX1 (0.45) | CYP1A2LSSEPHX1 | |
| SCHEMBL10456643 | 0.88 | EPHX1 (0.45) | CYP1A2LSSEPHX1 | |
| SCHEMBL4843720 | 0.88 | CYP1A2 (0.61) | CYP1A2LSSCNR2 | |
| SCHEMBL4842023 | 0.86 | CYP1A2 (0.65) | CYP1A2CNR2EPHX1 | |
| SCHEMBL6139215 | 0.86 | CYP1A2 (0.56) | CYP1A2LSSEPHX1S1PR2S1PR4 | |
| SCHEMBL30497000 | 0.86 | CYP1A2 (0.56) | CYP1A2LSSEPHX1S1PR2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099654-B1 | SYNTHETIC METHOD | UNIV COURT UNIV ST ANDREWS (GB) | 2018-05-09 | — | — | EP | disclosed |
| US-9908826-B2 | Synthetic method | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170174608-A1 | Synthetic Method | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2017-06-22 | — | — | US | disclosed |
| EP-3099654-A1 | SYNTHETIC METHOD | University Court of The University of St Andrews (GB) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015114323-A1 | SYNTHETIC METHOD | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174608-A1 | Synthetic Method | SQLE, FDFT1, CYP51A1 | CYP1A2 8/4885LSS 18/4885CNR2 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.